Skip to main content

Table 1 Absence of toxicity of RSG and QC in nasal mucosa explants

From: CCL2 and CCL5 driven attraction of CD172a+ monocytic cells during an equine herpesvirus type 1 (EHV-1) infection in equine nasal mucosa and the impact of two migration inhibitors, rosiglitazone (RSG) and quinacrine (QC)

Localization (nasal mucosa)

Products

Percentage (%) of TUNEL-positive cells treated at… μM at 72 hpi

0 (mock)

1

3

10

30

Epithelium

RSG

0.3 ± 0.2

0.4 ± 0.3

0.7 ± 0.6

0.6 ± 0.5

1.1 ± 0.6

QC

0.4 ± 0.1

0.7 ± 0.3

1.2 ± 0.6

1.4 ± 0.6

1.6 ± 0.7

Lamina propria

RSG

0.5 ± 0.6

1.4 ± 0.8

3.0 ± 0.7

2.8 ± 1.9

4.0 ± 1.1

QC

0.6 ± 0.2

1.2 ± 0.7

2.7 ± 0.9

3.2 ± 0.7

4.7 ± 1.6

  1. Viability of nasal mucosa explants treated with RSG or QC at different concentrations was determined in the TUNEL assay at 72 hpi. Values are given as mean ± SD of 3 different experiments.